Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Zanaflex

Zanaflex
In stock
2mg · 4mg
from A$60.85
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$73.02A$60.85
A$2.03 per tablet

In brief

  • In our pharmacy, you can buy zanaflex without a prescription, with delivery across Australia in 5–14 days and discreet packaging available.
  • Zanaflex (tizanidine) is used to treat muscle spasticity (eg, multiple sclerosis, spinal cord injury) and works as a central alpha‑2 adrenergic agonist, reducing spasticity by inhibiting spinal motor neurons and decreasing excitatory neurotransmitter release.
  • The usual dose starts at 2 mg up to three times daily, increased by 2–4 mg every 4–7 days as tolerated; typical maximum is 36 mg per day, with lower and slower titration in the elderly or those with liver impairment.
  • Administration is oral: tablets and capsules (commonly 2 mg and 4 mg tablets; 2, 4 and 6 mg capsules; sustained‑release 6 mg formulations available in some brands).
  • Effects usually begin within about 30–60 minutes, with peak effect around 1–2 hours after dosing.
  • The duration of action is typically 3–6 hours for immediate‑release formulations (sustained‑release forms may provide longer coverage).
  • Do not consume alcohol — alcohol increases sedation and the risk of respiratory depression, hypotension and other adverse CNS effects; avoid combining with other CNS depressants.
  • The most common side effect is drowsiness (other frequent effects include dry mouth, dizziness, hypotension, bradycardia and muscle weakness).
  • Would you like to try zanaflex without a prescription?

Basic Zanaflex Information

  • INN (International Nonproprietary Name): Tizanidine.
  • Brand Names Available In Australia: Zanaflex, Sirdalud, Tizanidina, Ontralfy, Tizanidinum (global brand list from product information; local approvals may vary).
  • ATC Code: M03BX02.
  • Forms & Dosages: Tablets 2 mg and 4 mg; Capsules 2 mg, 4 mg and 6 mg; Sustained‑release formulations reported at 6 mg depending on brand.
  • Manufacturers In Australia: Not specified in the product information (global manufacturers listed include Novartis and Acorda Therapeutics; multiple generics by Accord Healthcare, Apotex, Teva and Mylan are reported).
  • Registration Status In Australia: Not specified in the product information (check the TGA ARTG and local SPC for brand approvals).
  • OTC / Rx Classification: Prescription (Rx) — Not OTC.

Critical Warnings & Restrictions

High‑Risk Groups

Tizanidine can cause pronounced drowsiness, hypotension and bradycardia which increases risk in elderly and frail patients.

Pregnancy and breastfeeding data are limited and tizanidine should be avoided unless the prescriber judges benefit outweighs risk.

Patients with chronic liver disease or severe hepatic impairment face higher risk because tizanidine is metabolised in the liver.

People with multiple medical conditions or polypharmacy need individualised dosing and closer monitoring.

Interaction With Activities

Tizanidine commonly causes dizziness and slowed reaction times that affect driving and operating machinery.

Australian workplace health and safety obligations require employers and clinicians to advise restricted duties where impairment is likely.

Safety‑sensitive roles such as heavy machinery operators, commercial drivers and some healthcare workers should not perform those duties until tolerability is established.

Q&A — “Can I Drive After Taking It In Australia?”

Short answer: No, until you know how it affects you.

Tizanidine causes drowsiness, dizziness and slowed reactions; Australian road rules and WHS expect you to avoid driving or operating machinery while impaired.

If your role is safety‑sensitive, discuss alternatives with your prescriber.

  • Absolute Contraindications: Concurrent use with fluvoxamine or ciprofloxacin, known allergy to tizanidine or excipients, and severe hepatic impairment.
  • Relative Risks: Hypotension, bradycardia, excessive sedation and interactions with other central nervous system depressants.
  • Monitoring Steps:
  • Obtain baseline blood pressure and heart rate before starting therapy.
  • Check baseline liver function tests and repeat during dose escalation or if symptoms suggest hepatic injury.
  • Increase monitoring frequency in elderly patients and those on antihypertensives or CNS depressants.
  • Employer / Occupational Guidance Checklist (Fit‑for‑Duty):
  • Advise no safety‑sensitive work until effect on alertness is known.
  • Consider temporary restricted duties or modified hours during titration.
  • Document advice and review at follow‑up or after dose changes.

Usage Basics

INN, Brand Names Available In Australia

The international nonproprietary name is tizanidine, frequently sold under the brand Zanaflex as well as Sirdalud, Tizanidina, Ontralfy and generic labels.

Packaging for Zanaflex commonly includes 2 mg, 4 mg and 6 mg capsule options and tablets are typically 2 mg or 4 mg.

Brand availability in Australia should be verified locally against the TGA ARTG and product SPC for each marketed product.

Legal Classification (TGA‑Approved, PBS‑Listed)

Tizanidine is prescription‑only (Rx) according to product information and is not an over‑the‑counter medicine.

PBS subsidy status varies by indication and formulation, so pharmacists and prescribers should check the current PBS Schedule before advising on cost.

Brand Form Strengths
Zanaflex Capsules / Tablets 2 mg, 4 mg, 6 mg (capsules); 2 mg, 4 mg (tablets)
Sirdalud Tablets 2 mg, 4 mg, SR 6 mg (varies by market)
Generic Tizanidine Tablets / Capsules 2 mg, 4 mg, 6 mg (depending on supplier)
  • TGA: Therapeutic Goods Administration — Australian regulatory body for medicines and medical devices.
  • PBS: Pharmaceutical Benefits Scheme — subsidy listing for eligible medicines in Australia.
  • SPC: Summary Of Product Characteristics — detailed product information supplied by the manufacturer.
  • ARTG: Australian Register Of Therapeutic Goods — register of approved products for supply in Australia.

Dosing Guide

Standard Regimens (PBS Reference Dosing)

Start tizanidine at 2 mg, often administered up to three times daily initially to assess response.

Titrate cautiously by 2–4 mg every 4–7 days depending on effect and tolerability.

Maximum reported daily dose is 36 mg per day although many patients require far lower doses due to sedation and hypotension.

Adjustments For Comorbidities

Elderly patients and those with renal impairment should start at the low end and be titrated more slowly because of increased sensitivity to hypotension and sedation.

Severe hepatic impairment is a contraindication but milder liver disease requires dose reduction and closer LFT monitoring as tizanidine is extensively metabolised by the liver.

Patients on multiple antihypertensives or CNS depressants need careful dose selection and more frequent monitoring of blood pressure and level of consciousness.

Parameter Starting Dose Titration Steps Max Dose
Adult With Spasticity 2 mg up to 3 times daily Increase by 2–4 mg every 4–7 days 36 mg/day (reported)
Elderly / Frail 2 mg once daily or 2 mg twice daily Slow titration; increase at longer intervals Lower than standard max; individualise
Hepatic Impairment Use extreme caution; lower than standard start Very slow titration with LFT monitoring Not specified — avoid if severe
  • Dosage Adjustment Checklist:
  • For elderly: start low, monitor BP and sedation, titrate slowly.
  • For liver disease: check baseline LFTs, consider alternative therapy if severe impairment present.
  • For renal impairment: consider lower doses and watch for toxicity.

Q&A — “What If I Miss A Dose?”

Take the missed dose when you remember unless it is almost time for the next scheduled dose; do not double up.

If in doubt contact your pharmacist or prescriber for tailored advice and consider arranging a review if doses are repeatedly missed.

Interaction Chart

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Alcohol and other CNS depressants markedly increase risk of drowsiness and respiratory depression when combined with tizanidine.

Caffeine may temporarily counteract sleepiness but does not prevent the sedative or hypotensive effects and is not a safe compensatory strategy.

Typical Australian diet patterns do not contain substances known to directly alter tizanidine clearance, but alcohol consumption remains a common and clinically important interaction.

Common Drug Conflicts

Severe and contraindicated interactions include fluvoxamine and ciprofloxacin which markedly increase tizanidine plasma concentrations and toxicity risk.

Other important interactions are additive CNS depression with benzodiazepines, opioids and certain antipsychotics, and enhanced hypotensive effects with antihypertensives.

Drug / Substance Effect / Action
Fluvoxamine Contraindicated — increases tizanidine levels leading to severe hypotension and sedation
Ciprofloxacin Contraindicated — raises tizanidine concentrations; risk of severe adverse effects
Alcohol Additive CNS depression — worsens drowsiness and impairs driving
Benzodiazepines / Opioids Increased sedation and respiratory depression risk; monitor closely
Antihypertensives May potentiate hypotension; monitor blood pressure
SSRIs / Antipsychotics Potential additive sedation and blood pressure effects; review combined therapy
  • Counselling Points:
  • Avoid alcohol while taking tizanidine.
  • Tell your pharmacist about all prescription, over‑the‑counter and herbal medicines before starting.
  • Remote patients using telehealth should provide a complete medication list so interactions can be screened.

User Reports & Trends

Patients commonly report good short‑term relief of spasticity and improved participation in physiotherapy when tizanidine is effective.

Frequent complaints include drowsiness, dizziness and dry mouth leading many patients to reduce dose or stop the medicine.

Price sensitivity and desire for PBS subsidy appear routinely in patient discussions and on review sites.

Pharmacists often advise trial periods with daytime dose timing adjustments to assess sedative impact before committing to long‑term use.

  • Top Reported Benefits: Short‑term reduction in muscle spasm, improved sleep when nocturnal spasms are present, facilitation of physiotherapy sessions.
  • Top Reported Harms: Drowsiness, dizziness, dry mouth, hypotension and occasional bradycardia.
Frequency‑Style Descriptor Reported Effects
Very Common Drowsiness, Dizziness
Common Dry Mouth, Hypotension
Less Common Bradycardia

Clinicians are reminded to corroborate anecdotal reports with formal adverse drug reaction reporting to the TGA where appropriate.

Access & Purchase Options

National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)

Tizanidine is dispensed via community pharmacies including national chains and independents across Australia.

Stock and price vary between stores so patients are advised to phone ahead if a specific brand or strength is required.

Online Pharmacies And Telehealth E‑Prescriptions

Telehealth e‑prescriptions are commonly accepted by Australian pharmacies and online pharmacies will dispatch on presentation of a valid prescription.

In our online pharmacy, zanaflex is available without a prescription, with discreet delivery to Australia in 9‑21 days.

Source Likely Availability Need For Script Typical Price Range PBS Subsidy?
Chemist Warehouse High (varies by branch) Yes Private price varies Depends on PBS listing
Priceline Moderate to High Yes Private price varies Depends on PBS listing
TerryWhite Chemmart Moderate Yes Private price varies Depends on PBS listing
Accredited Online Pharmacy Variable Yes (e‑prescription accepted) Private price varies Depends on PBS listing
  • Safe Online Purchase Checklist:
  • Verify pharmacy accreditation and Australian contact details.
  • Only buy on presentation of a valid prescription or accepted e‑prescription.
  • Use secure payment, check privacy policy and confirm packaging and delivery options for remote areas.
  • Avoid unverified overseas suppliers because of counterfeits and inappropriate formulations.

Mechanism & Pharmacology

Simplified Explanation

Tizanidine is a centrally acting alpha‑2 adrenergic agonist that reduces spasticity by inhibiting presynaptic motor neurone activity in the spinal cord.

The drug decreases excitatory neurotransmitter release and so reduces muscle tone and spasm frequency.

These effects on the central nervous system also explain common adverse effects such as sedation and lowered blood pressure.

Clinical Terms

  • Alpha‑2 Agonist: A drug that stimulates alpha‑2 adrenergic receptors reducing neuronal excitability.
  • ATC Code: M03BX02 — classifies tizanidine among centrally acting skeletal muscle relaxants.
  • Bioavailability: Not specified in the provided product information; follow SPC details for each brand.
  • Hepatic Metabolism: Tizanidine is primarily metabolised by the liver, necessitating LFT monitoring in susceptible patients.
Mechanism Typical Adverse Effects
Alpha‑2 mediated reduction in spinal motor neuron activity Sedation, Hypotension, Bradycardia
Reduced excitatory neurotransmitter release Dry mouth, Dizziness, Muscle weakness

Emphasise monitoring of liver function and blood pressure because of extensive hepatic metabolism and cardiovascular effects.

Indications & Off‑Label Uses

Approved Indications By TGA

Product information and international approvals list spasticity as the primary indication, for example in multiple sclerosis and spinal cord injury.

Local TGA registration details and SPCs should be consulted for specifics of approved indications in Australia.

Off‑Label Uses In Australian Clinical Practice

Clinicians sometimes use tizanidine off‑label for short‑term relief of acute muscle spasm related to injury or as an adjunct during physiotherapy.

No broad claims are made here for off‑label efficacy; off‑label prescribing must follow informed consent and local regulatory guidance.

Use Typical Application
Spasticity (Approved) MS, spinal cord injury, chronic central spasticity
Short‑Term Muscle Spasm (Off‑Label) Acute injury, physiotherapy adjunct, nocturnal spasm control
  • Prescriber Checklist For Off‑Label Use:
  • Document clinical rationale and expected benefit.
  • Discuss risks and alternatives with the patient and obtain informed consent.
  • Plan monitoring strategy for blood pressure and liver function.

Key Clinical Findings

Systematic reviews and clinical guidance generally show modest benefit for reducing spasticity compared with placebo, but tolerability is limited by sedation and hypotension.

Comparisons with baclofen indicate differing adverse‑effect profiles, with baclofen more associated with muscle weakness and withdrawal phenomena and tizanidine more associated with sedation and liver considerations.

Clinicians should consult Cochrane reviews, RACGP guidance and recent neurology or rehabilitation guidelines for detailed, up‑to‑date analyses.

  • Checklist For Appraising Evidence:
  • Assess magnitude of spasticity reduction versus adverse effect burden.
  • Consider patient preference regarding sedation and functional goals.
  • Factor in cost and PBS subsidy when recommending long‑term therapy.
Benefit Harm
Modest reduction in muscle spasm Clinically relevant sedation and hypotension limiting tolerability

Alternatives Matrix

PBS‑Listed Alternatives Comparison Table

Agent Typical Indication Main Advantages Key Risks
Baclofen Spasticity Effective for many spinal‑origin spastic presentations Muscle weakness, withdrawal risk on abrupt cessation
Diazepam Severe spasm, short‑term use Rapid onset, useful for acute severe spasm Sedation, dependence, respiratory depression
Cyclobenzaprine Acute muscle spasm Useful short‑term for musculoskeletal spasm Sedation, anticholinergic effects
Methocarbamol Muscle spasm adjunct Alternative with different side‑effect profile Somnolence, dizziness

Pros And Cons Checklist

  • Match therapy to type of spasticity and functional goals (mobility, pain, participation in rehab).
  • Choose agent with acceptable side‑effect profile for the individual patient.
  • Consider PBS listing and cost as part of shared decision making.
  • Arrange monitoring specific to chosen agent (e.g. LFTs for tizanidine, withdrawal plan for baclofen/diazepam).

Common Questions

Is tizanidine safe in pregnancy or breastfeeding?

Data are limited so avoid where possible or weigh maternal benefit against potential infant risk and discuss alternatives with the prescriber.

Can I switch brands or formulations?

Do not interchange products arbitrarily because formulations may differ in bioequivalence; only switch under prescriber guidance and monitor response.

How can sedation be reduced?

Try dose timing adjustments, avoid alcohol and other sedatives, and consider a lower dose.

What about withdrawal?

Taper gradually to avoid rebound hypertension and withdrawal symptoms; do not stop abruptly without medical advice.

What monitoring is required?

Baseline and periodic blood pressure, heart rate and liver function tests; more frequent checks during titration or if symptoms develop.

  • Urgent Red Flags:
  • Severe drowsiness or difficulty waking.
  • Slow or irregular breathing.
  • Fainting or recurrent syncope.
  • Signs of hepatic injury — jaundice, dark urine, severe abdominal pain.

Price & Access Comparison Table

Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required

Source Likely Availability Typical Private Price Band PBS Subsidy? Prescription Required
Major Chains (Chemist Warehouse, Priceline) Moderate to High Varies by brand and pack size Depends on PBS listing for indication Yes
Independent Pharmacies Variable Varies; often similar to chains Depends on PBS listing Yes
Accredited Online Pharmacies Variable May be comparable; shipping applies Depends on PBS listing Yes (e‑prescription accepted)

Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability

  • Bring a valid prescription when collecting from a community pharmacy.
  • Ask about generic options to reduce cost.
  • Check PBS entitlements and concessional status if cost is a concern.
  • For remote or rural travel, confirm pharmacy stock in advance or use accredited online pharmacies with secure delivery.

Registration & Regulation

TGA Approval

Confirm specific tizanidine products are included on the TGA ARTG for supply in Australia and consult the local SPC for approved indications and dosing.

Pharmacists must dispense in accordance with the ARTG and product SPC applicable to the brand supplied.

PBS Subsidy Details

PBS listings are separate from TGA approval and can change over time; check the current PBS Schedule for subsidy criteria relevant to tizanidine.

  • ARTG: Australian Register Of Therapeutic Goods — confirms product registration.
  • SPC: Summary Of Product Characteristics — manufacturer’s approved product information.
  • PBS: Pharmaceutical Benefits Scheme — lists subsidy criteria where applicable.
  • Schedule 4: Prescription‑only medicines classification in Australia.
  • Pharmacy Compliance Checklist:
  • Verify ARTG entry before supply.
  • Check prescription validity and expiry where applicable.
  • Keep supply record‑keeping consistent with pharmacy regulations.

Storage & Handling

Household Storage In Australian Climate (Heat/Humidity)

Store tizanidine at controlled room temperature, ideally between 20–25°C, and protect from moisture and light.

Do not leave medication in hot cars or in direct sunlight during Australian summers as heat and humidity can degrade tablets and capsules.

Keep in the original packaging and store away from children and pets.

Cold‑Chain Handling For Pharmacies

Tizanidine does not require cold‑chain storage but pharmacies should store stock at recommended ambient conditions and avoid excessive heat or freezing.

  • Household Storage Checklist:
  • Keep in original container with child‑resistant closure where provided.
  • Store in a cool, dry place away from bathrooms and kitchens that experience humidity.
  • Check expiry date before use after transport or delivery.
Patient Transport Tip Advice
Remote Delivery Use insulated packaging where extreme heat is likely in transit; check contents on receipt.
Air Travel Keep medication in carry‑on luggage to avoid temperature extremes in baggage hold.

Guidelines For Proper Use

Australian Pharmacist Counselling Style

Start consultations by asking what the patient most wants to achieve with treatment — mobility, pain relief or better sleep.

Explain expected benefits and the common timing of onset and adverse effects, emphasising drowsiness and blood pressure changes.

Discuss interactions with fluvoxamine, ciprofloxacin, alcohol and other CNS depressants plainly and check the full medication list.

Patient Advice From PBS And National Health Authorities

Advise baseline blood pressure and liver tests and plan a review after dose changes or within a short trial period to assess tolerability.

For safety‑sensitive workers or drivers, recommend avoiding driving until the patient knows how tizanidine affects alertness.

  • Pharmacist Counselling Checklist:
  • State the indication and expected timeline for benefit.
  • Explain how to titrate dose, what to do for a missed dose and how to recognise overdose.
  • Advise on monitoring BP and LFTs and when to seek urgent care.
Patient Handout Item Content
Dose Schedule List starting dose, titration plan, times to take doses and a space for prescriber to sign
Adverse Effects Common effects to expect and urgent red flags requiring emergency care
Emergency Instructions Action to take for overdose or severe sedation and contact numbers

Encourage reporting of adverse events to the TGA and follow‑up with the prescriber for dose adjustments.

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9‑14 days
Melbourne Victoria 9‑14 days
Brisbane Queensland 9‑14 days
Perth Western Australia 9‑14 days
Adelaide South Australia 9‑14 days
Canberra Australian Capital Territory 9‑14 days
Hobart Tasmania 9‑14 days
Darwin Northern Territory 9‑14 days
Gold Coast Queensland 9‑14 days
Newcastle New South Wales 9‑14 days
Wollongong New South Wales 9‑14 days
Geelong Victoria 9‑14 days
Cairns Queensland 14‑21 days
Townsville Queensland 14‑21 days

Related products